NAD+ IV Therapy (300 mg)

NAD+ (nicotinamide adenine dinucleotide) administered intravenously at 300 mg over 2–3 hours. NAD+ is a coenzyme involved in cellular energy production and DNA repair that naturally declines with age. IV delivery provides systemic availability. Next Health Houston offers 300 mg and 750 mg doses. Sessions run 2–3 hours at a slow drip rate.

Next Health Houston's NAD+ IV Therapy delivers nicotinamide adenine dinucleotide — a coenzyme central to cellular energy metabolism — directly into the bloodstream, bypassing the limited oral bioavailability of NAD+ precursor supplements. NAD+ serves as an electron carrier in the mitochondrial electron transport chain (complexes I and III), enabling ATP synthesis via oxidative phosphorylation; it is also consumed by enzymes involved in DNA repair (PARP-1), sirtuin longevity protein activation (SIRT1–7), and cAMP signalling. Plasma NAD+ levels decline progressively with age, and this decline has been associated in preclinical research with impaired mitochondrial function, reduced cellular repair capacity, and hallmarks of biological ageing. The 300 mg dose at Next Health Houston provides a foundational NAD+ infusion and is the standard starting point for patients new to IV NAD+ therapy. The slow infusion rate — typically over 2–3 hours — is used because rapid NAD+ delivery can cause transient symptoms including chest tightness, nausea, and muscle cramping as the molecule is metabolised in tissues throughout the body; the extended drip time allows the body to process it more comfortably. A 750 mg dose ($1,000) is available for patients seeking a higher systemic loading. Clinical staff monitor the patient throughout the session. The treatment is part of Next Health's longevity and performance optimisation menu alongside ozone therapy, therapeutic plasma exchange, and biomarker testing. Regular repeat sessions — typically monthly or quarterly — are the approach taken by Next Health members as part of a sustained optimisation programme.